Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam in pediatric nosocomial pneumonia
NCT04223752Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of ceftolozane + tazobactam in hospital-acquired pneumonia (HAP) (5 arms), sponsored by Merck & Co. Primary endpoints: Adverse Events at 31 days, Serious Adverse Events at 31 days and 3 more. Started Apr 2020; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT04223752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223752.